CREATING A BETTER FUTURE FOR FAMILIES AFFECTED BY RARE DISEASE

Travere Therapeutics is determined to bring life-changing treatments, support, and hope to people with rare disease—an area often overlooked.

PEOPLE LIVING WITH RARE DISEASE AND THEIR families know what it's like to search endlessly in the hopes of finding a research study for their diagnosis—often to no avail. Many parents of children born with rare disease recall the moment when they were told: "There's no treatment option available." These are the real-life, heartbreaking experiences of the 30 million people in America living with rare disease.

Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies to people living with rare disease. Headquartered in San Diego, with operations in Europe, the company's 300 employees have a unique understanding of rare disease. Together, they've cultivated a culture of compassion and integrity, thanks to a deep-rooted commitment to the rare disease community. With many of its own employees impacted by rare disease themselves, this mission is personal.

"Our dedication to rare patients, caregivers, and advocates is a lifelong commitment, and it's integral to who we are as an organization," says Eric Dube, Ph.D., president and CEO of Travere. "This commitment extends beyond developing life-changing therapeutics: It means working together with patients to support their needs to the best of our ability."

Travere is working with patient advocates to enhance newborn screening for rare diseases at both the state and federal levels. The company also champions access to care for underserved communities, and promotes access to telehealth and new ways to support caregivers and care partners of people living with rare disease.

Travere is inspired by the people it serves today and those it aspires to serve in the future. By Jamela G., who has never known a day without the restrictions placed on her by classical homocystinuria (HCU), a rare metabolic disorder; by Gisela D., whose careful habits as a young adult were no match for her rapidly progressing IgA nephropathy; and by Kevin M., who cycled through difficult side effects from medications not indicated for his rare kidney disease, focal segmental glomerulosclerosis (FSGS), until he reached kidney failure.

Travere has two of the largest ongoing clinical trials to date in rare kidney disease and is hoping to bring a new approved treatment option for kidney patients like Gisela and Kevin. In addition, Travere is evaluating what could potentially become the first disease-modifying therapy for people living with classical HCU, like Jamela.

"In rare disease, you don't go it alone," says Dube. "This is a powerful community of patients, families, physicians, researchers, and advocates who come together to prove time and again that we are stronger together. That is what drives this era of change. And it's what inspires us at Travere to be in rare for life." ■

"Our dedication to rare patients, caregivers, and advocates is a lifelong commitment, and it's integral to who we are as an organization."

ERIC DUBE, PH.D.
President and CEO
Travere Therapeutics